Biotech News
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-May-Proceed" letter SINGAPORE and NORTH BRUNSWICK, N.J., Sept.